MX2022005111A - Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52). - Google Patents

Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).

Info

Publication number
MX2022005111A
MX2022005111A MX2022005111A MX2022005111A MX2022005111A MX 2022005111 A MX2022005111 A MX 2022005111A MX 2022005111 A MX2022005111 A MX 2022005111A MX 2022005111 A MX2022005111 A MX 2022005111A MX 2022005111 A MX2022005111 A MX 2022005111A
Authority
MX
Mexico
Prior art keywords
gpr52
modulator compounds
compounds
ameliorating
disclosures
Prior art date
Application number
MX2022005111A
Other languages
English (en)
Inventor
Michael Alistair O'brien
Nigel Alan Swain
Sarah Joanne Bucknell
Stephen Paul Watson
Graaf Chris De
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1916298.1A external-priority patent/GB201916298D0/en
Priority claimed from GBGB1918992.7A external-priority patent/GB201918992D0/en
Priority claimed from GBGB1918974.5A external-priority patent/GB201918974D0/en
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of MX2022005111A publication Critical patent/MX2022005111A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Las descripciones del presente documento se refieren a nuevos compuestos de la Fórmula (1): (ver Fórmula) (1) y sales de los mismos, en donde R1, Q, X, Y y Z se definen aquí, y a su uso en el tratamiento, prevención, mejora, control o reducción del riesgo de trastornos asociados con los receptores GPR52.
MX2022005111A 2019-11-08 2020-11-09 Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52). MX2022005111A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1916298.1A GB201916298D0 (en) 2019-11-08 2019-11-08 GPR52 modulator compounds
GBGB1918992.7A GB201918992D0 (en) 2019-12-20 2019-12-20 GPR52 modulator compounds
GBGB1918974.5A GB201918974D0 (en) 2019-12-20 2019-12-20 Gpr52 modulator compounds
PCT/GB2020/052832 WO2021090030A1 (en) 2019-11-08 2020-11-09 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
MX2022005111A true MX2022005111A (es) 2022-05-30

Family

ID=73344101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005111A MX2022005111A (es) 2019-11-08 2020-11-09 Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).

Country Status (10)

Country Link
US (1) US20230002374A1 (es)
EP (1) EP4055016A1 (es)
JP (1) JP2023501984A (es)
KR (1) KR20220098156A (es)
CN (1) CN114650992A (es)
AU (1) AU2020381168A1 (es)
BR (1) BR112022008685A2 (es)
CA (1) CA3156474A1 (es)
MX (1) MX2022005111A (es)
WO (1) WO2021090030A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202013558D0 (en) * 2020-08-28 2020-10-14 Heptares Therapeutics Ltd GRP52 Modularor compounds
CN117940420A (zh) 2021-09-14 2024-04-26 勃林格殷格翰国际有限公司 3-苯氧基氮杂环丁烷-1-基-杂芳基吡咯烷衍生物及其作为药物的用途
GB202113186D0 (en) * 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
EP4289427A1 (en) 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100097077A (ko) * 2009-02-25 2010-09-02 주식회사 중외제약 Ｈｓｐ90에 대한 억제 효능을 갖는 피리디논 유도체
ES2784316T3 (es) 2015-04-29 2020-09-24 Arena Pharm Inc 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo
JP2019536820A (ja) * 2016-12-01 2019-12-19 アプトセ バイオサイエンシーズ インコーポレイテッド Ｂｒａｄ４およびｊａｋ２の二重阻害剤としての縮合環式ピリミジン化合物、ならびにその使用に関する方法
AU2018350989A1 (en) * 2017-10-17 2020-05-28 Epizyme, Inc. Amine-substituted heterocyclic compounds as EHMT2 inhibitors and derivatives thereof

Also Published As

Publication number Publication date
CA3156474A1 (en) 2021-05-14
JP2023501984A (ja) 2023-01-20
EP4055016A1 (en) 2022-09-14
CN114650992A (zh) 2022-06-21
AU2020381168A1 (en) 2022-04-14
US20230002374A1 (en) 2023-01-05
KR20220098156A (ko) 2022-07-11
BR112022008685A2 (pt) 2022-07-26
WO2021090030A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
MX2022005111A (es) Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).
MX2022011333A (es) Compuestos moduladores de gpr52.
MX2022010040A (es) Compuestos moduladores de gcn2.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
GEP20217227B (en) Novel phenyl derivatives
MX2018012379A (es) Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
CR20210235A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
CR20200373A (es) Compuestos
GEP20247646B (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
PH12021550558A1 (en) Modulators of pnpla3 expression
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
PH12017500800A1 (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
PH12020551995A1 (en) Modulator of apol1 expression
MX2022000811A (es) Inhibidores de enzimas.
PH12021551053A1 (en) Modulators of irf5 expression
PH12019501566A1 (en) Amide compounds and use thereof
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2020007369A (es) Moduladores de la expresion de dnm2.
MX2022002470A (es) Inhibidores de dihidroorotato deshidrogenasa sustituidos con urea.
CA3156131A1 (en) PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS
GB2532641A (en) 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators